Clinical Trial Update: A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 biomarker study in patients with metastatic colorectal cancer evaluating regorafenib. The trial was terminated and results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Sponsor: Georgetown University | Conditions: Colon Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-01-29